Indication: Hypertension

A multi-center, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of Aliskiren in pediatric hypertensive patients 6-17 years of age.

Sub-indication: Hypertension

Drug Study

Principal Investigator: Janice Sullivan, M.D.
Norton Children's Critical Care, affiliated with the UofL School of Medicine

Sponsor: Novartis Pharmaceuticals Corp

Search our entire site.